Clinical trials: Meloxicam
Osteoarthritis
A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee
To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days
- Trial name
- NCT02183116
- Testing
- Meloxicam
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Pharyngitis
Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis
The objective of this study was to assess the clinical efficacy and safety of meloxicam suspension 0.25 mg/kg/day once a day, versus diclofenac suspension 1 mg/kg/day twice a day or nimesulide suspension 4 mg/kg/day twice a day…
- Trial name
- NCT02229747
- Testing
- Meloxicam, Diclofenac, Nimesulide
- Volunteers
- 128 people
- Sponsor
- Boehringer Ingelheim
Migraine
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
- Trial name
- NCT05550207
- Testing
- AXS-07 (meloxicam-rizatriptan)
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Axsome Therapeutics, Inc.
Arthritis, Rheumatoid
Observational Study of Meloxicam in Any Labeled Indication
Evaluation on the amelioration of symptom intensity of the indication and to evaluate drug tolerability.
- Trial name
- NCT02182739
- Testing
- Meloxicam
- Volunteers
- 13,039 people
- Sponsor
- Boehringer Ingelheim
Dysmenorrhea
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic…
- Trial name
- NCT02183025
- Testing
- Meloxicam 7.5 mg, Meloxicam 15 mg, Mefenamic acid 500 mg
- Volunteers
- 337 people
- Sponsor
- Boehringer Ingelheim
Migraine
Initiating Early Control of Migraine Pain and Associated Symptoms
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults.
- Trial name
- INTERCEPT (NCT04163185)
- Testing
- AXS-07 (MoSEIC meloxicam and rizatriptan)
- Where
- 41 sites in United States
- Volunteers
- 302 people
- Sponsor
- Axsome Therapeutics, Inc.
Osteoarthritis
Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee
To assess the efficacy and safety of meloxicam 7.5mg once daily compared with diclofenac 100mg SR once daily over a treatment period of 8 weeks
- Trial name
- NCT02183129
- Testing
- Diclofenac, Meloxicam
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Healthy
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
The primary purpose of this study was to evaluate the effect of meloxicam tablets (7.5, 15 mg and 30 mg) with meloxicam placebo.
- Trial name
- NCT02183155
- Testing
- Meloxicam - low, Meloxicam - medium, Meloxicam - high
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Osteoarthritis
Postmarketing Surveillance Study With MOBEC®
The aim of the study is to investigate the indication for MOBEC in a dose of 15 mg per day the treatments patients were receiving before switching to 15 mg MOBEC how treatment with 15 mg is assessed compared with previous…
- Trial name
- NCT02182726
- Testing
- MOBEC
- Volunteers
- 4,760 people
- Sponsor
- Boehringer Ingelheim
Pain
Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar
To assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg administered in a single dose, over an…
- Trial name
- NCT02183051
- Testing
- Meloxicam 7.5 mg, Meloxicam 3.75 mg, Meloxicam 1.875 mg
- Volunteers
- 381 people
- Sponsor
- Boehringer Ingelheim
Arthritis, Rheumatoid
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis.
- Trial name
- NCT00042068
- Testing
- Meloxicam
- Where
- 153 sites in United States, Argentina and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Boehringer Ingelheim
Healthy
Meloxicam 15 mg Tablets Under Non-Fasting Conditions
The objective of this study is to compare the rate and extent of absorption of meloxicam from a test formulation Meloxicam 15 mg Tablets versus the reference Mobic® 15 mg Tablets under fed conditions.
- Trial name
- NCT00840879
- Testing
- Meloxicam 15 mg Tablets, Mobic® 15 mg Tablets
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Pharyngitis
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis
Study to assess the efficacy and tolerability of Meloxicam once daily dose of 7.5 mg and 15 mg compared with 1100 mg of naproxen sodium in the symptomatic treatment of acute non bacterial pharyngitis or pharyngo-tonsillitis, over…
- Trial name
- NCT02183038
- Testing
- Meloxicam low, Meloxicam high, Naproxen sodium
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Pharmacokinetics
Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition
The aim of the study was to compare the bioavailability of two formulations of meloxicam given to healthy volunteers and to demonstrate bioequivalence.
- Trial name
- NCT05125588
- Testing
- Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine), Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"
Healthy
Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition
The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Boehringer Ingelheim Pharmaceuticals Inc.…
- Trial name
- NCT01161134
- Testing
- Meloxicam
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Post Operative Pain
Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery
This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to <17 years.
- Trial name
- NCT05315479
- Testing
- N1539
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Baudax Bio
Healthy
Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg
The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x 15 mg) dose administration under fasting…
- Trial name
- NCT00649077
- Testing
- Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Healthy
Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects
Study to gain information on the percutaneous absorption of meloxicam after administration of a topical gel over 7 days.
- Trial name
- NCT02183077
- Testing
- Meloxicam gel, Meloxicam tablet
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
Primary Objective: To access the bioequivalence of meloxicam capsule 15 mg (Test, T) to meloxicam tablet 15mg (Reference, R) following oral administration.
- Trial name
- NCT02183181
- Testing
- Meloxicam capsule, Meloxicam tablet
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Participants With Acute Moderate to Severe Pain Following Abdominal Surgery
Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery
This study aims to evaluate the analgesic efficacy and safety of meloxicam injection in subjects with moderate-to-severe pain following abdominal surgery.
- Trial name
- NCT06904248
- Testing
- Meloxicam Injection, Sodium Chloride Injection
- Where
- 18 sites in China
- Volunteers
- 224 people
- Sponsor
- Yangtze River Pharmaceutical Group Co., Ltd.